Clinic Software← All companies
Gismo Therapeutics (United States)
Innovative Therapeutics for Alzheimer's and Parkinson's Disease
health AI/biotech startup focused on neurodegenerative diseases
StagePrivately held, funded by private investors and grant awards
Raised$235,000
Founded2013
Employees3
LocationLexington, KY
Business modelB2B/B2C SaaS-like therapeutics development with research collaboration potential (not explicitly stated)
Valuation$17,800,000
About
GISMO THERAPEUTICS INC. is a privately funded biotech start-up company incorporated in 2011. The company is developing novel oral therapeutics for Alzheimer’s and Parkinson's Disease, based on a novel hypothesis and a novel mechanism of action. Gismo Therapeutics Inc. has ongoing research collaborations with US academic institutions.
Product
- Value proposition
- Developing first-in-class, disease-modifying oral therapeutics for Alzheimer’s and Parkinson’s diseases based on the GISMO technology.
Founders
- Paul Gregor — Founder and Chief Executive Officer
Categories
Products
GISMO-based therapeutics (first-in-class, disease-modifying oral therapeutics)
Key features
Targeting fundamental biochemical processes in neurodegenerative disease pathogenesisFirst-in-class, disease-modifying oral therapeuticsGISMO technology as the basis of the platformawarded research grants supporting development
Technologies
GISMO technologyoral therapeuticsneurodegenerative disease biology
Target conditions
Alzheimer's diseaseParkinson's disease
Care settings
clinical researchlaboratory researchhospital/clinic (treatment context as a product development company)
Investors
Harvey CohenMichael J. Fox Foundation for Parkinson’s DiseaseNIH (SBIR grants)
News
- Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof - Patent Application · 2024-12-05T05:00:00.000Z
- BioTech & BioPharma - Greater Lexington · 2024-08-28T00:00:00.000Z
- GC Therapeutics: Changing the Future of Cell Therapies · 2025-05-01T03:22:54.000Z
- Pharmacosmos Group to Acquire G1 Therapeutics · 2024-08-07T10:29:00.000Z
- GC Therapeutics Launches to Scale and Unlock the Next Generation of Cell Therapy — GC Therapeutics · 2024-09-19T10:28:00.000Z
